PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $24 | -100.0% | 637 | -30.4% | 0.00% | – |
| Q3 2022 | $48,000 | -21.3% | 915 | -14.0% | 0.00% | – |
| Q2 2022 | $61,000 | -18.7% | 1,064 | +8.2% | 0.00% | – |
| Q1 2022 | $75,000 | +29.3% | 983 | +0.7% | 0.00% | – |
| Q4 2021 | $58,000 | -10.8% | 976 | -16.2% | 0.00% | – |
| Q3 2021 | $65,000 | -4.4% | 1,165 | +2.8% | 0.00% | – |
| Q2 2021 | $68,000 | -6.8% | 1,133 | +7.9% | 0.00% | – |
| Q1 2021 | $73,000 | +17.7% | 1,050 | +1.3% | 0.00% | – |
| Q4 2020 | $62,000 | +14.8% | 1,037 | +14.7% | 0.00% | -100.0% |
| Q3 2020 | $54,000 | +237.5% | 904 | +200.3% | 0.00% | – |
| Q2 2020 | $16,000 | +33.3% | 301 | -17.1% | 0.00% | – |
| Q1 2020 | $12,000 | +33.3% | 363 | +81.5% | 0.00% | – |
| Q4 2019 | $9,000 | +12.5% | 200 | 0.0% | 0.00% | – |
| Q3 2019 | $8,000 | +33.3% | 200 | +22.7% | 0.00% | – |
| Q1 2019 | $6,000 | – | 163 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GAGNON SECURITIES LLC | 563,415 | $21,753,453 | 4.80% |
| Gagnon Advisors, LLC | 180,331 | $6,962,579 | 4.70% |
| Spyglass Capital Management LLC | 868,686 | $33,539,966 | 2.69% |
| Tamarack Advisers, LP | 100,000 | $3,861,000 | 1.99% |
| ARMISTICE CAPITAL, LLC | 1,892,000 | $73,050,120 | 1.27% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 276,590 | $10,679,140 | 0.99% |
| RICE HALL JAMES & ASSOCIATES, LLC | 437,285 | $16,883,574 | 0.97% |
| Rock Springs Capital Management LP | 1,032,600 | $39,868,686 | 0.96% |
| OUTFITTER FINANCIAL LLC | 25,860 | $998,455 | 0.91% |
| Stephens Investment Management Group LLC | 1,168,469 | $45,535,237 | 0.82% |